Today

DavosPharma is a leading provider of discovery services and custom cGMP manufacturing of APIs, NCEs, and Biologics. We supply custom products and services from sites all over the world to deliver the best solutions for our clients’ specific needs, timelines and budgets.

  • Manufacturing – Our vast network can handle any drug production

  • Results Orientated – We only get paid on deliverables

  • Research Led – Discovery within budget and regulation

Our Service Model is managed by some of the industry’s most qualified chemists, process engineers, analysts, project managers, and pharmaceutical marketing experts.

History

DavosPharma was established in 1972 by H Barry Robins as Davos Chemical Corporation. Initially, DavosPharma specialized in the oil based commodity and specialty chemicals market.

As the market evolved, DavosPharma rose to meet the needs of its clients. Gradually, we moved into custom manufacturing of raw materials and intermediates for specialty chemicals and into the outsourcing model for custom starting materials and advanced intermediates.

Today, DavosPharma continues to grow and expand to meet the needs of the marketplace. Our unique experience combined with the skills of our talented Tech Ops Team positions us to offer our clients the tremendous technical capabilities of manufacturers worldwide.

As we look to the future, DavosPharma continues to expand its portfolio by exploring new initiatives in drug discovery, formulation services, and ‘electroceuticals.’

Drug discovery continues to change and expand and so too will DavosPharma.

Meet Our Team

Custom chemistry, biology and formulation is our business.

H. Barry RobinsFounder - Chairman of the Board
H. Barry Robins founded DavosPharma in 1972. He started his business career with ICI, Canada as a Process Engineer. Mr. Robins then worked for ICC, New York, where he held the position of Vice President, Marketing. Mr. Robins holds a B.Sc. in Chemical Engineering from Queens University, Kingston, Ontario.
Brian S. RobinsCo - CEO
Brian Robins joined DavosPharma in 1994. He focused on a number of multinational and emerging pharmaceutical companies, developing six clinical candidates. Three of these NCE projects are in late Phase III clinical trials, and one is awaiting FDA approval. Prior to joining DavosPharma, Mr. Robins worked at Delmar Chemical in Montreal. Mr. Robins holds a B.Sc. in Chemical Engineering from Queen’s University, Kingston, Ontario.
David A. RobinsCo - CEO
David Robins has been instrumental in expanding DavosPharma from strictly manufacturing and marketing of small molecule building blocks for active substances to a full service provider. Under his leadership, DavosPharma now supports all manufacturing, biology and regulatory needs for commercial and IND drug development. Prior to joining Davos, Mr. Robins was a lead Process Engineer at Bristol-Myers Squibb where he was responsible for the scale up and tech transfer of several late stage and commercial drugs. Mr. Robins received his B.S. in Engineering Chemistry from Queen’s University in Kingston, Ontario and M.S. in Chemical Engineering from Syracuse University.
Anthony DelPreteExecutive Vice President and Chief Financial Officer
Anthony DelPrete’s primary responsibilities include the ongoing development and risk management of DavosPharma’s financial operations’ strategy. He manages all aspects of the company’s finances and internal operations, including confidentiality agreements (CDAs), contract negotiations, legal and insurance matters. Mr. DelPrete began his career with DavosPharma in 1982. He holds a B.A. in Marketing from Pace University and a M.B.A. in Finance from Iona College.
Suzanne EpsteinBusiness Manager
Suzanne Epstein has been with Davos for 17 years. Her main job function today includes managing and reviewing confidential disclosure agreements, master services agreements and supply agreements. She also assists the field sales representatives their daily roles. Prior to joining Davos, Ms. Epstein was a technical sales representative for Witco Corporation and bench chemist at Sun Chemical. She has a Bachelor of Science and Natural History from Muhlenberg College and a Master’s of Business Administration in Marketing from Montclair State University.
George T. GeorgesExecutive Vice President of Sales
George Georges joined DavosPharma in 2013. He is responsible for business development in the New England area. Prior to joining DavosPharma, Mr. Georges was a Global Account Manager for Avantor Performance Materials (formerly Mallinckrodt Baker) for ten years. In his role, he managed the cGMP Pharma chemicals portfolio at a number of large BioPharma accounts and many biotech startups in the Boston area. Before joining Avantor, Mr. Georges started his career in nanotechnology at Triton Systems managing SBIR programs on high performance coatings and barrier polymers. Mr. Georges earned his B.S. in Chemistry from the University of Massachusetts, Amherst and an MBA from Babson College.
Matt CwiklinskiDirector, Business Development
Matt Cwiklinski joined DavosPharma in 2019. His responsibilities include developing new business in Southern California and the Midwest. Prior to joining Davos, he spent 12 years developing new customers for Olon Ricerca (formerly Ricerca Biosciences), Apiscent Labs, LLC (formerly Fontarome Chemical), and Cambridge Major Laboratories (now part of Sterling Pharma). During these years, he developed relationships with emerging biotech to large multi-national pharma clients to bring their APIs from concept to commercial. Prior to Business Development, Matt spent 10 years performing process development, scale up, and cGMP manufacturing with Cambridge Major Laboratories. Matt received his B.S. in Chemistry from the University of Minnesota – Twin Cities.
Charles BonnefondTechnical Marketing Manager
Charles brings 10 years of process development experience to DavosPharma working in biopharma on pre-clinical and clinical development programs. Prior to DavosPharma, Charles served as project manager at Flamma Honkai in Dalian, China, assisting in the process development and manufacturing of RSMs and early step intermediates for NCE APIs before transitioning to the business development team of the Flamma Group in Paris, France. Prior to Flamma, Charles worked in Bacterial Downstream and Upstream development at Merial in the R&D labs of Lyon, France and Athens, GA. In his time at Merial, Charles’ work focused on optimizing high-density cultures of E. coli either producing sc pDNA as a cancer vaccine candidate for cats, or overexpressing a recombinant protein as an infectious disease vaccine candidate for dogs, as well as developing the downstream processes.
Charles received his bachelor’s in chemistry and chemical engineering degree from CPE LYON prior to joining the biopharmaceutical industry.
Conor HoulihanLogistics Coordinator
Conor Houlihan joined DavosPharma in 2017. He is responsible for the internal support of import/export logistics and database management. He holds a B.S. in Chemical Engineering from the State University at Buffalo.
Michael KatesVP, Integrated IND/NDA Program Development
Dr. Michael Kates joined DavosPharma in 2011. He is responsible for business development and management of Davos’ fully Integrated Drug Discovery Service Platform. Prior to this, he worked as a medicinal chemist at both Wyeth Laboratories and DuPont-Merck. He holds a B.S. degree in chemistry, a Ph.D. from Villanova University and Post Doctorial Research Fellow at Brown University. Dr. Kates is an Adjunct Associate Professor Medicinal Chemistry at the University of New England, School of Pharmacy and has 21 publications and contributed talks.
Vance LyonSenior Director
​Dr. Lyon joined DavosPharma in 1998. He is responsible for project management and new business development of custom chemistry resources for both emerging and multinational pharmaceutical companies. ​Prior to joining DavosPharma, Dr. Lyon was Director of Analytical Services and Quality Assurance at Chemir Polytech Laboratories and Director of Marketing and QA at Parish Chemical. Dr. Lyon holds a Ph.D. in Synthetic Organic Chemistry from the University of Utah and a B.S. from the University of Chicago.
Greg BydlinskiDirector, Chemistry - Montreal, Canada
Greg Bydlinski joined DavosPharma in 2016. He is responsible for business development in Canada while providing technical support in the New England area. Prior to joining DavosPharma, Dr. Bydlinski was a Business Development Manager/R&D Director/R&D Supervisor/Senior Scientist with Delmar Chemicals, Montreal over a period of twenty years. Dr. Bydlinski started his process chemistry career in 1987 at Ciba-Geigy, Summit, NJ. Dr. Bydlinski earned his BA in Chemistry and Psychobiology from Hamilton College, Clinton, NY. Subsequently, he earned his MSc and PhD from Emory University, Atlanta, GA.
Lucja OrzechowskiProject Manager
Lucja Orzechowski joined DavosPharma in January 2017. Her primary role is to monitor activities to ensure timely delivery of goods, reports and project-related data. Prior to joining Davos she worked as a Medicinal Chemist at Roche and was a Quality Assurance Auditor at Lohmann Therapy Systems. She holds a B.S. degree in Food Science from Lodz University of Technology in Poland and a M.S. in Organic Chemistry from Montclair State University.
Muppala S. RajuVice President, Chemistry
Dr. Muppala Raju joined DavosPharma in 1995. He is responsible for the development of DavosPharma’ business activities in India. Dr. Raju is also head of chemistry at DavosPharma where he directs the process development of all contracted projects at DavosPharma’ worldwide custom manufacturers. Prior to joining DavosPharma, Dr. Raju held several positions including Manager of Chemical Process R&D for Celgene Corporation. He was also a Research Scientist for Rhône-Poulenc Research Center, Research Chemist for PPG Industries and held post doctoral positions at the University of Iowa and Rockefeller University. Dr. Raju has co-authored fifteen research publications and has been issued six patents. He holds a Ph.D. from Rice University and an MBA from Kent State University.
Michael E. ShoreDirector, Project Management & API Development - San Francisco, CA
Micheal Shore joined DavosPharma in 2007. He is responsible for business development with the emerging biotech and pharmaceutical companies in the Bay Area and Pacific Northwest. Prior to DavosPharma, Mike began his career with Ciba-Geigy as a process chemist. He then joinied Agouron Pharmaceuticals/WarnerLambert/Pfizer where he was responsible for process development, scale-up, optimization, technology transfer, validation and the manufacture of Viracept®, Agouron’s small molecule protease inhibitor. Mr. Shore has also worked at Amylin Pharmaceuticals as a Project Manager. Mr. Shore holds a B.S. degree in Organic Chemistry from Florida State University. He has also had direct involvement with the filing of six INDs and two NDAs.
Shobhana SridharanTechnical Sales Coordinator
Shobhana Sridharan joined the DavosPharma in 2005. Her responsibilities include inside sales and database management. She holds an M.S. in Food and Nutrition from Women’s University in India.
Alicia ZucattiDirector, Import/Export Logistics
Alicia Zucatti joined DavosPharma in 1985. She is responsible for all import/export logistics and documentation required for US, EU and Japanese regulatory agencies (OSHA, EPA, DOT, IATA,) and legislation (TSCA, Right to Know, MITI, C-TPAT and REACH). Ms. Zucatti holds a B.A. from Pace University.

We Deliver

Whether your company has ten employees or ten thousand, DavosPharma has the resources and energy to deliver the discovery, toxicology, biologics, chemistry, and formulation services you need.